BioNTech
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
University of Pennsylvania Sues BioNTech Over Unpaid COVID-19 Vaccine Royalties
University of Pennsylvania, BioNTech, COVID-19 vaccine, patent royalties, lawsuit
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology
BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo
FDA Halts BioNTech-MediLink ADC Trial Due to ‘Significant Risk of Illness or Injuries’
FDA, BioNTech, MediLink, ADC, Clinical Trial, Safety Concerns, Cancer Treatment
BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa
BioNTech, CEPI, mRNA vaccine production, Africa, vaccine equity, public health security
BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion
BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology
BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront
BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.